1,169 件 ・ 関連度順
概要と使いどころ
作業パターンを skill 化すべきか判定する共通スキル。org-retro と org-curate から呼ばれ、 「skill 化推奨 / 候補止まり / curated ノートのまま」の 3 値と根拠を返す。 自動 skill 化はせず、推奨は machine-local な knowledge/skill-candidates.local.md に追記し、 窓口が候補キューが溜まった時点でバッチで人間に問い合わせる二段構え。
Use when the user wants a final packaged video from an approved project and the project satisfies Gate 10 packaging prerequisites.
日本語の概要は準備中です。原文の説明を表示しています。
This skill covers detecting cyber attacks targeting Supervisory Control and Data Acquisition (SCADA) systems including man-in-the-middle attacks on industrial protocols, unauthorized command injection into PLCs, HMI compromise, historian data manipulation, and denial-of-service against control system communications. It leverages OT-specific intrusion detection systems, industrial protocol anomaly detection, and process data analytics to identify attacks that traditional IT security tools miss.
日本語の概要は準備中です。原文の説明を表示しています。
Responds to security incidents in cloud environments (AWS, Azure, GCP) by performing identity-based containment, cloud-native log analysis, resource isolation, and forensic evidence acquisition adapted for ephemeral cloud infrastructure. Activates for requests involving cloud incident response, AWS security incident, Azure compromise, GCP breach, cloud forensics, or cloud identity compromise.
日本語の概要は準備中です。原文の説明を表示しています。
Performs Linux memory acquisition using LiME (Linux Memory Extractor) kernel module and analysis with Volatility 3 framework. Extracts process lists, network connections, bash history, loaded kernel modules, and injected code from Linux memory images. Use when performing incident response on compromised Linux systems.
日本語の概要は準備中です。原文の説明を表示しています。
Create forensically sound bit-for-bit disk images using dd and dcfldd while preserving evidence integrity through hash verification.
日本語の概要は準備中です。原文の説明を表示しています。
Diagnose why a data warehouse sync is failing and recommend the right recovery action. Use when the user asks "why isn't my Stripe/Postgres/Hubspot sync working?", "this table has been stuck for hours", "the data in the warehouse looks wrong", or wants to troubleshoot a specific source or schema. Covers source-level vs schema-level failures, stuck Running states, credential and schema-drift errors, incremental-field misconfig, CDC prerequisite failures, and the cancel / reload / resync / delete-data recovery actions.
日本語の概要は準備中です。原文の説明を表示しています。
Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.
日本語の概要は準備中です。原文の説明を表示しています。
Synthesize scientific evidence into a claim-to-source matrix, distinguish primary evidence from interpretation, assess disagreement and study limitations, and produce a calibrated research summary.
日本語の概要は準備中です。原文の説明を表示しています。
Mendelian randomization (MR) causal inference — does an exposure, risk factor, or biomarker CAUSALLY affect a disease/outcome, using genetic variants as instrumental variables (IEU OpenGWAS / EpiGraphDB MR-EvE). Use this whenever the user asks if X causes Y, whether an observational association is actually causal or just correlation, if a biomarker/trait is a causal risk factor, wants to triangulate epidemiology against genetic evidence, or mentions Mendelian randomization, instrumental-variable analysis, two-sample MR, or genetic causal evidence — even if they never say "MR" (e.g. "is LDL cholesterol actually causal for heart disease?", "does BMI cause type 2 diabetes or just correlate?", "is CRP a causal driver of stroke?"). Covers trait-label resolution, MR effect direction/magnitude, instrument quality (MOE score), method agreement (IVW vs MR-Egger vs weighted median), bidirectional MR for reverse causation, and distinguishing causation from genetic correlation. Not for plain GWAS association lookups (use the GWAS skills) or fitting your own instruments from raw summary statistics.
日本語の概要は準備中です。原文の説明を表示しています。
Designs genomics experiments so technical nuisance variation (batch, lane, plate, flow cell, operator, reagent lot, processing day) is balanced against the biological variable of interest and therefore estimable rather than confounded, using constrained sample-to-batch assignment (designit, OSAT), the confounder/mediator/collider distinction, and the principle that no post-hoc correction recovers a fully confounded design. Covers detecting hidden batches with surrogate variable analysis, a decision table for downstream correction (ComBat-seq, RUVSeq, SVA) whose execution is deferred to differential-expression/batch-correction, and reproducibility metadata. Use when assigning samples to sequencing batches/lanes/plates, avoiding batch-condition confounding, deciding whether a design is salvageable by correction, choosing a correction method, or estimating the number of hidden batches. For the experimental unit, randomization, and blocking concepts see experimental-design/randomization-blocking.
日本語の概要は準備中です。原文の説明を表示しています。
End-to-end imaging mass cytometry workflow from raw acquisitions to spatial cell analysis. Orchestrates image preprocessing, segmentation, phenotyping, and spatial statistics. Use when analyzing imaging mass cytometry data end-to-end.
日本語の概要は準備中です。原文の説明を表示しています。
Chemical safety and toxicology assessment integrating ADMET-AI predictions, CTD toxicogenomics, PubChemTox experimental data, GHS/IARC hazard classification, and exposure-context analysis. Use for chemical hazard identification, occupational/consumer-product toxicity, dose-response evaluation, and acute (LD50) vs chronic toxicity assessment. Distinguishes drug toxicity from environmental chemical toxicity.
日本語の概要は準備中です。原文の説明を表示しています。
Optimize tool descriptions in ToolUniverse JSON configs for clarity and usability. Reviews descriptions for missing prerequisites, unexpanded abbreviations, unclear parameters, and missing usage guidance. Use when reviewing tool descriptions, improving API documentation, or when user asks to check if tools are easy to understand.
日本語の概要は準備中です。原文の説明を表示しています。
KEGG-based disease-drug-variant network research. Connects diseases to causal genes, drugs to molecular targets, and variants to pathways using KEGG's editorially curated databases (KEGG Disease, Drug, Network, Variant, Pathway). Use for drug repurposing via shared pathways, mechanistic disease-gene-drug networks, and pathway-based target discovery. Distinguishes direct (binding) vs indirect (pathway co-membership) drug-target relationships.
日本語の概要は準備中です。原文の説明を表示しています。
Assigns honest lipid annotation levels, designs class-based internal-standard quantification, and runs lipid-aware differential and enrichment analysis with lipidr, guarding against in-source-fragment phantoms, sn-position over-claims, and invalid cross-class quantification. Use when naming or canonicalizing lipid species (shorthand separators, Goslin), deciding shotgun vs RP vs HILIC LC-MS, picking internal standards (SPLASH/EquiSPLASH), interpreting MS-DIAL/LipidSearch output, or comparing lipid classes. For general feature detection see metabolomics/xcms-preprocessing and metabolomics/msdial-preprocessing; for non-lipid annotation confidence see metabolomics/metabolite-annotation; for normalization/QC see metabolomics/normalization-qc; for multivariate stats see metabolomics/statistical-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Builds production-quality, accessible, responsive user-facing UIs. Use when building or modifying interfaces and pages, creating components, implementing layouts, meeting WCAG accessibility requirements, managing state, or when the output needs to look and feel production-quality rather than AI-generated.
日本語の概要は準備中です。原文の説明を表示しています。
Reads and changes a running CARLA server's WorldSettings via apply_settings — synchronous vs asynchronous mode, fixed_delta_seconds (fps), physics substepping, and no_rendering_mode — and keeps the Traffic Manager's sync state matched automatically. Use when the user asks to "enable/disable sync mode", "set synchronous mode", "run at a fixed fps/step", "turn off rendering", "make the sim deterministic", or "restore async mode", and as the prerequisite for keeping settings across a map load.
日本語の概要は準備中です。原文の説明を表示しています。
Sistema completo de due diligence para transacciones M&A en España. Abarca análisis jurídico (mercantil, regulatorio, compliance), fiscal (CIT, IVA, retenciones, facturación electrónica) y medioambiental (licencias, pasivos, responsabilidad). Incluye matrices de riesgo cuantitativas, workflows de ejecución, templates de informes y referencias normativas BOE/UE/ISO actualizadas. Úsalo cuando el usuario solicite due diligence en España, análisis de riesgos transaccionales, evaluación pre-adquisición o auditoría de cumplimiento normativo para share deals o asset deals.
日本語の概要は準備中です。原文の説明を表示しています。
Detects and removes contamination in genome assemblies via two disjoint workflows - foreign-sequence screening of a single-organism (eukaryote/isolate) assembly with NCBI FCS-GX (GenBank-submission-mandatory), FCS-adaptor, and BlobToolKit blob plots; and MAG/bin quality assessment with CheckM2 plus GUNC (chimerism) plus GTDB-Tk taxonomy, judged against MIMAG. Covers why CheckM2 alone is blind to disjoint-marker chimeras, the FCS-GX RAM wall, organelle/NUMT triage, strain heterogeneity, and the HGT-vs-contamination (tardigrade) trap. Use when screening an assembly for foreign contamination before GenBank submission, assessing MAG completeness/contamination/chimerism, deciding which contigs to remove, or distinguishing real HGT from contaminant contigs.
日本語の概要は準備中です。原文の説明を表示しています。
Orders and orients assembled contigs into chromosome-scale scaffolds from long-range linking data, inserting N-gap spacers (adds no sequence). Covers Hi-C/Omni-C scaffolding (YaHS, SALSA2, 3D-DNA/Juicer), Hi-C read-mapping prerequisites (map each end separately, no mate rescue, dedup, enzyme-aware), reading the contact map for misjoins/inversions/false-duplications, manual curation in Juicebox/PretextView (the VGP/DToL standard), reference-guided scaffolding (RagTag) and its karyotype-erasure hazard, genetic-map (ALLMAPS) and Bionano optical-map integration, chimera-breaking before scaffolding, gap-filling, and telomere/contig-vs-scaffold-N50 QC (tidk). Use when turning contigs into chromosomes with Hi-C, integrating a linkage map or optical map, choosing a scaffolder by available linking data, or judging whether a chromosome-scale assembly is trustworthy.
日本語の概要は準備中です。原文の説明を表示しています。
Nominates and assesses CRISPR off-target sites genome-wide. Enumerates candidate sites by mismatch and bulge tolerance with Cas-OFFinder/CRISPRitz, ranks them with the published CFD score (SpCas9-only, relative ranker) or MIT/CRISTA/energy models, runs variant-aware screening against gnomAD/individual genomes (CRISPRme), and frames the empirical genome-wide discovery assays (GUIDE-seq, CIRCLE-seq, CHANGE-seq, DISCOVER-seq, Digenome-seq) and high-fidelity nuclease choice (HiFi Cas9, Sniper-Cas9, eSpCas9, SpCas9-HF1). Use when assessing guide RNA specificity, choosing among candidate guides, screening a therapeutic guide against population variation, or planning empirical off-target validation. Distinguishes predicted vs detected vs validated. On-target activity scoring and deaminase (Cas-independent) base/prime-editor off-targets are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Evaluates genome assembly quality across the three orthogonal axes - contiguity (QUAST auN/NG50/NGx, not bare N50), completeness (BUSCO/compleasm gene-space plus Merqury k-mer completeness), and correctness (reference-free Merqury QV, Inspector/CRAQ structural errors, asmgene false-duplication/collapse). Covers why N50 is the most-gamed metric, why QV measured on the polishing reads is circular, distinguishing uncollapsed haplotigs from real WGD, and the EBP/VGP 6.C.Q40 standard. Use when judging whether an assembly is good enough to annotate or publish, comparing assemblers, diagnosing a fragmented or duplicated assembly, or assessing a phased diploid assembly.
日本語の概要は準備中です。原文の説明を表示しています。
Detects focal chromatin loops (point interactions / corner-dots) in balanced Hi-C and Micro-C contact maps and aggregates/validates a loop set. Covers de-novo calling with cooltools dots (HiCCUPS-style 4-background local enrichment with lambda-chunked FDR), chromosight (template-correlation), and Mustache (scale-space blob detection); aggregate peak analysis (APA) via cooltools pileup for confirmation; the depth/resolution prerequisite (de-novo needs ~5-10kb resolution = hundreds of millions to billions of valid pairs); consensus across callers and convergent-CTCF support as validation; and differential loops via union anchors plus chromosight quantify. Use when calling chromatin loops or dots from a cooler, deciding whether a map is deep enough to call de-novo vs running APA on known CTCF/cohesin anchors, building an aggregate peak pileup, comparing loops across conditions, or validating loop calls. For HiChIP/PLAC-seq/PCHi-C protein-anchored data use FitHiChIP/MAPS, not dots.
日本語の概要は準備中です。原文の説明を表示しています。